Eledon Pharmaceuticals (ELDN) Accounts Payables (2013 - 2026)

Eledon Pharmaceuticals has reported Accounts Payables for 14 years, with the latest figure at $6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 126.99% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (up 126.99% YoY), and the FY2025 full-year result was $3.6 million, down 37.82% from the prior year.
• Accounts Payables for Q1 2026 stood at $6.6 million, up from $3.6 million in the prior quarter.
• The five-year high for Accounts Payables was $6.6 million in Q1 2026, with the low at $465000.0 in Q3 2023.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 87.95% — and 2024, when it surged 1160.22%.
• Eledon Pharmaceuticals' Accounts Payables stood at $2.2 million in 2022, then sank by 56.05% to $967000.0 in 2023, then surged by 503.21% to $5.8 million in 2024, then plunged by 37.82% to $3.6 million in 2025, then soared by 81.56% to $6.6 million in 2026.
• The last three Accounts Payables figures came in at $6.6 million (Q1 2026), $3.6 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.